Cargando…

Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model

Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-García, Cristina, Izquierdo, Adriana, Velagapudi, Vidya, Vivas, Yurena, Velasco, Ismael, Campbell, Mark, Burling, Keith, Cava, Fernando, Ros, Manuel, Orešič, Matej, Vidal-Puig, Antonio, Medina-Gomez, Gema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Limited 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424461/
https://www.ncbi.nlm.nih.gov/pubmed/22773754
http://dx.doi.org/10.1242/dmm.009266
_version_ 1782241216899842048
author Martínez-García, Cristina
Izquierdo, Adriana
Velagapudi, Vidya
Vivas, Yurena
Velasco, Ismael
Campbell, Mark
Burling, Keith
Cava, Fernando
Ros, Manuel
Orešič, Matej
Vidal-Puig, Antonio
Medina-Gomez, Gema
author_facet Martínez-García, Cristina
Izquierdo, Adriana
Velagapudi, Vidya
Vivas, Yurena
Velasco, Ismael
Campbell, Mark
Burling, Keith
Cava, Fernando
Ros, Manuel
Orešič, Matej
Vidal-Puig, Antonio
Medina-Gomez, Gema
author_sort Martínez-García, Cristina
collection PubMed
description Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology of diabetic nephropathy is debated. We generated a murine model, the POKO mouse, obtained by crossing the peroxisome proliferator-activated receptor gamma 2 (PPARγ2) knockout (KO) mouse into a genetically obese ob/ob background. We have previously shown that the POKO mice showed: hyperphagia, insulin resistance, hyperglycaemia and dyslipidaemia as early as 4 weeks of age, and developed a complete loss of normal β-cell function by 16 weeks of age. Metabolic phenotyping of the POKO model has led to investigation of the structural and functional changes in the kidney and changes in blood pressure in these mice. Here we demonstrate that the POKO mouse is a model of renal disease that is accelerated by high levels of glucose and lipid accumulation. Similar to ob/ob mice, at 4 weeks of age these animals exhibited an increased urinary albumin:creatinine ratio and significantly increased blood pressure, but in contrast showed a significant increase in the renal hypertrophy index and an associated increase in p27(Kip1) expression compared with their obese littermates. Moreover, at 4 weeks of age POKO mice showed insulin resistance, an alteration of lipid metabolism and glomeruli damage associated with increased transforming growth factor beta (TGFβ) and parathyroid hormone-related protein (PTHrP) expression. At this age, levels of proinflammatory molecules, such as monocyte chemoattractant protein-1 (MCP-1), and fibrotic factors were also increased at the glomerular level compared with levels in ob/ob mice. At 12 weeks of age, renal damage was fully established. These data suggest an accelerated lesion through glucolipotoxic effects in the renal pathogenesis in POKO mice.
format Online
Article
Text
id pubmed-3424461
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Company of Biologists Limited
record_format MEDLINE/PubMed
spelling pubmed-34244612012-09-01 Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model Martínez-García, Cristina Izquierdo, Adriana Velagapudi, Vidya Vivas, Yurena Velasco, Ismael Campbell, Mark Burling, Keith Cava, Fernando Ros, Manuel Orešič, Matej Vidal-Puig, Antonio Medina-Gomez, Gema Dis Model Mech Research Article Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology of diabetic nephropathy is debated. We generated a murine model, the POKO mouse, obtained by crossing the peroxisome proliferator-activated receptor gamma 2 (PPARγ2) knockout (KO) mouse into a genetically obese ob/ob background. We have previously shown that the POKO mice showed: hyperphagia, insulin resistance, hyperglycaemia and dyslipidaemia as early as 4 weeks of age, and developed a complete loss of normal β-cell function by 16 weeks of age. Metabolic phenotyping of the POKO model has led to investigation of the structural and functional changes in the kidney and changes in blood pressure in these mice. Here we demonstrate that the POKO mouse is a model of renal disease that is accelerated by high levels of glucose and lipid accumulation. Similar to ob/ob mice, at 4 weeks of age these animals exhibited an increased urinary albumin:creatinine ratio and significantly increased blood pressure, but in contrast showed a significant increase in the renal hypertrophy index and an associated increase in p27(Kip1) expression compared with their obese littermates. Moreover, at 4 weeks of age POKO mice showed insulin resistance, an alteration of lipid metabolism and glomeruli damage associated with increased transforming growth factor beta (TGFβ) and parathyroid hormone-related protein (PTHrP) expression. At this age, levels of proinflammatory molecules, such as monocyte chemoattractant protein-1 (MCP-1), and fibrotic factors were also increased at the glomerular level compared with levels in ob/ob mice. At 12 weeks of age, renal damage was fully established. These data suggest an accelerated lesion through glucolipotoxic effects in the renal pathogenesis in POKO mice. The Company of Biologists Limited 2012-09 2012-07-05 /pmc/articles/PMC3424461/ /pubmed/22773754 http://dx.doi.org/10.1242/dmm.009266 Text en © 2012. Published by The Company of Biologists Ltd This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.
spellingShingle Research Article
Martínez-García, Cristina
Izquierdo, Adriana
Velagapudi, Vidya
Vivas, Yurena
Velasco, Ismael
Campbell, Mark
Burling, Keith
Cava, Fernando
Ros, Manuel
Orešič, Matej
Vidal-Puig, Antonio
Medina-Gomez, Gema
Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title_full Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title_fullStr Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title_full_unstemmed Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title_short Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
title_sort accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424461/
https://www.ncbi.nlm.nih.gov/pubmed/22773754
http://dx.doi.org/10.1242/dmm.009266
work_keys_str_mv AT martinezgarciacristina acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT izquierdoadriana acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT velagapudividya acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT vivasyurena acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT velascoismael acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT campbellmark acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT burlingkeith acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT cavafernando acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT rosmanuel acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT oresicmatej acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT vidalpuigantonio acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel
AT medinagomezgema acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel